Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since 2002.
The objective of the FAVOR study was to evaluate the effect of indacaterol/glycopyrronium (IND/GLY) versus tiotropium on peak forced expiratory volume in 1 s (FEV1) and also to investigate patient satisfaction and treatment preference.
Boehringer presented data from the ANHELTO 1&2 studies (NCT01694771/NCT01696058) that evaluated the co-administration of Spiriva HandiHaler (tiotropium bromide inhalation powder)...
Tiotropium, a once-daily anticholinergic, and salmeterol represent two inhaled, long-acting bronchodilators from different pharmacologic classes.
Positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, �UMEC/VI�), from...
Background: COPD guidelines recommend the combined use of inhaled long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) if symptoms are not improved by a single agent.
Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and health care expenditure throughout the world. COPD guidelines recommend the use of long-acting muscarinic antagonist ...
Theravance Biopharma, Inc. and Mylan N.V. announced that positive new data from the companies' Phase III clinical program for Yupelri...